Results 251 to 260 of about 268,104 (311)

Impact of anti-VEGF therapy on choroidal thickness in patients with retinal vein occlusion: a systematic review and meta-analysis. [PDF]

Front Med (Lausanne)
Cheng X, Zeng X, Liu S, Liu C, Liu Y, Xu G.   +5 more
europepmc   +1 more source

DME-RWKV: An Interpretable Multimodal Deep Learning Framework for Predicting Anti-VEGF Response in Diabetic Macular Edema. [PDF]

Bioengineering (Basel)
Liu Y, Xu X, Zhang J, Wang H, Shen A, Song X, Xu X, Fu Y.   +7 more
europepmc   +1 more source

ANTI-VEGF TREATMENT Safety of intravitreal anti-VEGFs during pregnancy is unclear

, 2012
Georgalas, Ilias, Petrou, Petros, Koutsandrea, Chrysanthi   +2 more
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Anti-VEGF and Retinal Dystrophies

Current Drug Targets, 2020
The therapeutic approach based on anti-vascular endothelial growth factor (anti-VEGF) molecules can be used to treat two important complications of retinal dystrophies: choroidal neovascularization and macular edema. The macular involvement in retinal dystrophies can lead to further visual deterioration in patients at a young age and already affected
Battaglia Parodi Maurizio, Iacono Pierluigi, Da Pozzo Stefano   +2 more
openaire   +3 more sources

Anti-VEGF

2010
The development of therapy with anti-angiogenics or vascular endothelial growth factor inhibitors (anti-VEGF) has marked the beginning of a new era in neovascularization and macular edema treatment. Its main goals are the inhibition of growth and development of new vessels along with the reduction of vascular permeability.
BANDELLO , FRANCESCO, Battaglia Parodi M.   +1 more
openaire   +3 more sources

Resistance to Anti-VEGF Agents

Current Pharmaceutical Design, 2004
The number of anti-angiogenic agents developed for clinical use has risen greatly over the past decade. Currently, more than 80 are in trials ranging from phase I through to phase III studies and many more are in preclinical evaluation. Much hope was envisaged for these new agents to become the panacea of anti-tumoural treatment.
Ton, N. C., Jayson, G. C.
openaire   +2 more sources